Want to join the conversation?
Pharmacy benefit manager $ESRX reported a jump in 2Q16 earnings driven by lower costs and expenses despite a slight decline in revenues. Net income rose to $720.7MM or $1.13 per share from $600.1MM or $0.88 per share last year. Revenues slid to $25.22Bil from $25.45Bil. Adjusted EPS grew to $1.57 from $1.44.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?